R&D

Looking to early-stage companies for innovation, with Juerge...
In an interview at BIO 2025, Bayer's Juergen Eckhardt discusses the importance of external innovation and why his company is prioritising early stage.
R&D

Going wide on immune system activation, with Jeffrey Meckler
Indaptus CEO Jeff Meckler discusses his company's unconventional approach to immunotherapy, based on activating a wide swath of the immune system.
Oncology

BioNTech’s ASCO 2025 oncology advances: New data on bispecif...
At ASCO 2025, BioNTech presented 7 abstracts on four selected pipeline candidates in mesothelioma, lung cancer, prostate cancer, and melanoma.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
Newsletters and Deep Dive
digital magazine